Lower mortality risk associated with remdesivir plus corticosteroids vs corticosteroids alone for the treatment of patients hospitalized with SARS-CoV-2 infection in the early and later Omicron periods
Remdesivir plus CCS was associated with a significant reduction in inpatient all-cause mortality relative to CCS alone in patients hospitalized for COVID-19 across 3 years of the Omicron period, illustrating the utility of the most recent real-world evidence to help inform treatment recommendations for inpatient providers treating patients with SARS-CoV-2 infection.
Authors
- Natasha N. Pettit
- R L Gottlieb
- Chidinma Chima-Melton (ORCID: https://orcid.org/0000-0003-0730-9871)
- Amin An
- Aastha Chandak (ORCID: https://orcid.org/0000-0001-5653-435X)
- Andre C Kalil
- Thomas Oppelt
Institutions
- Université TÉLUQ (CA)
- University of California, Irvine (US)
- Baylor University Medical Center (US)
- University of Chicago (US)
- Cardiopulmonary Research Science and Technology Institute (US)
- Irvine University (US)
- Gilead Sciences (Australia) (AU)
- Baylor Scott & White Health (US)
- University of Nebraska Medical Center (US)
Publication Details
- Journal
- American Journal of Health-System Pharmacy
- Published
- 2026-02-05
- DOI
- https://doi.org/10.1093/ajhp/zxag034
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00